In with the old—and the new—for faster medical tests

Combing old science with new developments has led to a faster method of receiving results for HIV, Lyme disease, syphilis, rotavirus and other infectious conditions.

Shawn Putnam, an assistant professor in the University of Central Florida (UCF)'s College of Engineering & Computer Science, combined a magnetic phenomenon called the Faraday rotation, discovered over 170 years ago, with nanoscience to create tests for a multitude of infectious conditions.

"I see no reason why a variation of this technique couldn't be in every hospital throughout the world," said Putnam.

In the research study, published in Small , Putnam was able to cover nanoparticles with a bovine serum albumin antibody, which is used as the base in many diagnostic tests. Taking the nanoparticle and mixing it into a solution that binds the BAS proteins with the antibodies, Putnam then develop a new way to measure the number of proteins present by using iron core nanoparticles and a magnetic field to align the nanoparticles in a particular formation that revels the number of proteins with laser optics.   

This method can be used to produced biochemical immunology test results in 15 minutes, compared to waiting hours for standard biomolecule tests. The BSA protein can be substituted with other antigens for a broader spectrum of possible medical test.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.